Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADA | P00813 | 16/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | STAT1 | P42224 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4584440 | 0.85 | ADA (0.44) | ADANPC1HPGDNFKB1STAT1 | |
| SCHEMBL4583749 | 0.84 | ADA (0.49) | ADA | |
| SCHEMBL4584124 | 0.81 | ADA (0.49) | ADA | |
| SCHEMBL4584144 | 0.78 | ADA (0.50) | ADANPC1RAB9A | |
| SCHEMBL4584396 | 0.78 | ADA (0.40) | ADA | |
| SCHEMBL4582655 | 0.77 | ADA (0.51) | ADANPC1RAB9A | |
| SCHEMBL4585451 | 0.77 | ADA (0.59) | ADAHPGD | |
| SCHEMBL4584805 | 0.77 | ADA (0.49) | ADAHPGD | |
| SCHEMBL4584358 | 0.77 | ADA (0.49) | ADA | |
| SCHEMBL4584014 | 0.76 | ADA (0.48) | ADAHPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7317107-B2 | Imidazole 4-carboxamide compounds with adenosine deaminase inhibiting activity | ASTELLAS PHARMA INC. (JP) | 2008-01-08 | — | — | US | disclosed |
| US-20050159462-A1 | Imidazole 4-carboxamide compounds with adenosine deaminase inhibiting activity | ASTELLAS PHARMA INC. (JP) | 2005-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159462-A1 | Imidazole 4-carboxamide compounds with adenosine deaminase inhibiting activity | ADA, AMPD2, AMPD1 | ADA 1/4885NPC1 1630/4885HPGD 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.